Lung Cancer Edition: Top Headlines for Week of March 11, 2024
Manage episode 407442245 series 3560281
In this edition, race identified as risk factor for VTE, FDA approves Rybrevant for treatment of non-small cell lung cancer and more. Read the full coverage here:
Race identified as risk factor for VTE after pulmonary resection for lung cancer
FDA approves Rybrevant for treatment of non-small cell lung cancer
Behavioral health disorders have a ‘big impact’ on cancer surgery outcomes
Optimizing immunotherapy, biomarker testing vital to progress in lung cancer treatment
FDA approves Tagrisso plus chemotherapy for EGFR-mutated non-small cell lung cancer
References:
Axtell AL, et al. Ann Thorac Surg. 2024;doi:10.1016/j.athoracsur.2024.01.005.
Katayama ES, et al. J Am Coll Surgeons. 2024;doi:10.1097/XCS.0000000000000954.
119 حلقات